Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH
(WorldNews Canada)

Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH - Event featuring renowned myelofibrosis expert Dr. Ruben Mesascheduled for 7:00 am ETon December 8th - - Data highlighting decreased transfusion requirements for patients treated with momelotinib directly compared to ruxolitinib to be reported in a poster at ASH - VANCOUVER, Dec. 2, 2019/CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it will host an Analyst &...